Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.90 |
| ▸ | CA1 | P00915 | 10/20 | 0.90 |
| ▸ | CA12 | O43570 | 9/20 | 0.90 |
| ▸ | CA9 | Q16790 | 9/20 | 0.90 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.90 |
| ▸ | STAT3 | P40763 | 2/20 | 0.59 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23812256 | 0.84 | CA12 (0.66) | CA2CA1CA12CA9CA14 | |
| SCHEMBL25007822 | 0.84 | CA12 (0.66) | CA2CA1CA12CA9CA14 | |
| Hydrazine SCHEMBL10771056 | 0.82 | CA12 (0.62) | CA2CA1CA12CA9CA14 | |
| SCHEMBL109451 | 0.82 | CA1 (0.61) | CA2CA1CA12CA9CA14 | |
| SCHEMBL3899241 | 0.82 | CA12 (0.64) | CA2CA1CA12CA9CA14 | |
| SCHEMBL947826 | 0.80 | STAT3 (0.72) | CA2CA1CA12CA9CA14 | |
| SCHEMBL1178941 | 0.79 | CA2 (0.89) | CA2CA1CA12CA9CA14 | |
| SCHEMBL9389530 | 0.79 | CA2 (0.59) | CA2CA1CA12CA9CA14 | |
| SCHEMBL380152 | 0.77 | CA12 (0.57) | CA2CA1CA12CA9CA14 | |
| SCHEMBL21015615 | 0.77 | CA1 (0.57) | CA2CA1CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296551-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | DAIICHI SANKYO CO LTD (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2463268-B1 | 4-(Aminomethyl)benzoic acids as intermediates for the preparation of chymase inhibiting 1,4-diazepan-2,5-dione compounds | DAIICHI SANKYO CO LTD (JP) | 2013-08-28 | — | — | EP | disclosed |
| US-8507714-B2 | 7-membered ring compound and method of production and pharmaceutical application thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-08-13 | — | — | US | disclosed |
| CN-102127023-B | 7-membered ring compound, process for producing the same, and use thereof | DAIICHI SANKYO CO LTD | 2013-02-06 | — | — | CN | disclosed |
| EP-1820798-B1 | 7-MEMBERED RING COMPOUND, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | DAIICHI SANKYO CO LTD (JP) | 2012-08-22 | — | — | EP | disclosed |
| CN-101495463-B | Seven-membered ring compound, production method thereof and pharmaceutical use thereof | DAIICHI SANKYO CO LTD | 2012-08-15 | — | — | CN | disclosed |
| EP-2463268-A1 | Aminomethyl-substituted aromatic acids as intermediates for the preparation of chymase inhibiting 1,4-diazepan-2,5-dione compounds | Daiichi Sankyo Company, Limited (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-8049006-B2 | 7-membered ring compound and method of production and pharmaceutical application thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| CN-102127023-A | 7-membered ring compound, process for producing the same, and use thereof | DAIICHI ASUBIO PHARMA CO LTD | 2011-07-20 | — | — | CN | disclosed |
| US-20110166342-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| US-7385066-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-10 | — | — | US | disclosed |
| US-7385066-B2 | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-10 | — | — | US | disclosed |
| CN-101160290-A | 7-membered ring compound, process for producing the same, and pharmaceutical use thereof | ASUBIO PHARMA CO LTD (JP) | 2008-04-09 | — | — | CN | disclosed |
| EP-1863785-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING CMPLEMENT-MEDIATED DESEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-12 | — | — | EP | disclosed |
| EP-1820798-A1 | 7-MEMBERED RING COMPOUND, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | Asubio Pharma Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| WO-2006101860-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006101860-A1 | NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066667-A1 | Novel thiophene sulfoximines, compositions thereof, and methods treating complement-mediated diseases and conditions | C5, C1QBP, C1R | CA2 2365/4885CA1 1696/4885CA12 945/4885 |
| US-20130296551-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | CA2 187/4885CA1 418/4885CA12 352/4885 |
| US-20110166342-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | CA2 187/4885CA1 418/4885CA12 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.